A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD [coronary heart disease].

Trial Profile

A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD [coronary heart disease].

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Ezetimibe; Rosuvastatin; Simvastatin
  • Indications Coronary disorders; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms GRAVITY
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology.
    • 03 Nov 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top